Factors influencing efficacy endpoints in clinical trials for new oral medicinal treatments for overactive bladder: a systematic literature review and meta-analysis
- 75 Downloads
Overactive bladder (OAB) is a symptom-based disease; therefore, clinical trials to evaluate treatments for OAB employ a range of efficacy endpoints. Since factors that influence efficacy endpoints can affect trial outcomes, their identification could aid in the design of future OAB clinical trials. We investigated factors influencing different efficacy endpoints used in clinical trials with OAB patients and examined their characteristics to determine future clinical trial strategies for new medicinal treatments for OAB.
Data from placebo-controlled double-blind trials in patients with OAB were extracted via a systematic literature review. The integrated differences for efficacy endpoints were calculated. Heterogeneity was assessed using the Q statistic and I2 statistic. Factors influencing efficacy endpoints were identified through univariate and multivariate meta-regression analyses.
Forty-one controlled trials were analyzed. Substantial heterogeneity between studies was observed for each efficacy endpoint (P > 0.001, I2 > 70%). We found with multivariate meta-regression analysis that period of recording in a bladder diary and year of publication were significantly likely to influence the change from baseline in the mean number of urgency episodes in 24 h, year of publication and gender were significantly likely to influence the change from baseline in the mean number of micturitions in 24 h, and gender was significantly likely to influence the change from baseline in the mean volume voided per micturition. In contrast, there were no factors significantly associated with change from baseline in the mean number of incontinence episodes in 24 h.
We identified that change from baseline in the mean number of incontinence episodes in 24 h should serve as a relatively stable endpoint. In contrast, we identified factors influencing other endpoints, and the identified factors should be taken into account when planning and conducting future clinical trials.
KeywordsInfluencing factor Overactive bladder Randomized controlled trial Meta-analysis
Editorial support was provided by Kentarou Kuroishi from Astellas Pharma, Inc., and Andrew Lewis from Astellas Pharma Global Development, Inc.
Compliance with ethical standards
Conflict of interest
The authors have no conflicts of interest that are directly relevant to this research. Shingo Iino is an employee of Astellas Pharma, Inc.
- 9.EMA (2013) Guideline on the clinical investigation of medicinal products for the treatment of urinary incontinence. CPMP/EWP/18/01/Rev.1. London. (cited 2015 June 13) URL: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2013/07/WC500146177.pdf
- 10.PFSB (2006) Guidelines for clinical evaluation of drug for overactive bladder or incontinence. Notification No. 0628001 of the Evaluation and Licensing Division. Tokyo. (cited 2015 June 13) https://www.pmda.go.jp/files/000206216.pdf
- 13.R Foundation for Statistical Computing. R: a language and environment for statistical computing. https://www.R-project.org/. Accessed 1 Feb 2018
- 17.Herschorn S, Barkin J, Castro-Diaz D et al (2013) A phase III, randomized, double-blind, parallel-group, placebo-controlled, multicentre study to assess the efficacy and safety of the beta(3) adrenoceptor agonist, mirabegron, in patients with symptoms of overactive bladder. Urology 82(2):313–320CrossRefPubMedGoogle Scholar
- 21.Digesu GA, Verdi E, Cardozo L, Olivieri L, Khullar V, Colli E (2012) Phase IIb, multicenter, double-blind, randomized, placebo-controlled, parallel-group study to determine effects of elocalcitol in women with overactive bladder and idiopathic detrusor overactivity. Urology 80(1):48–54CrossRefPubMedGoogle Scholar
- 26.Chu F, Smith N, Uchida T (2009) Efficacy and safety of solifenacin succinate 10 mg once daily: a multicenter, phase III, randomized, double-blind, placebo-controlled, parallel-group trial in patients with overactive bladder. Curr Ther Res Clin Exp 70(6):405–420CrossRefPubMedPubMedCentralGoogle Scholar
- 49.Yamaguchi O, Marui E, Kakizaki H et al (2006) Solifenacin succinate phase II clinical trial—dose-finding study. Jpn Pharmacol Ther 2006(34):S47–S67Google Scholar
- 52.Bayer (2000) A study to assess if 10 mg Vardenafil (BAY38-9456) taken twice daily for 6 weeks has an effect on bladder function. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). [cited 2015 Jun 13]. https://clinicaltrials.gov/ct2/show/NCT00478881?term=NCT00478881&rank=1. NLM Identifier: NCT00478881
- 53.Sunovion, Dainippon Sumitomo Pharma America, ICON Clinical Research, ClinPhone ICP (2000) SMP-986 phase 2 proof of concept in patients with overactive bladder syndrome (OABS). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). [2015 Jun 13]. https://clinicaltrials.gov/ct2/show/NCT00409539?term=NCT00409539&rank=1. NLM Identifier: NCT00409539
- 54.Astellas Pharma Inc. (2000) Study of 2 doses of solifenacin succinate in female subjects with overactive bladder. (SHRINK). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). [2015 Jun 13]. https://clinicaltrials.gov/ct2/show/NCT01093534?term=NCT01093534&rank=1. NLM Identifier: NCT01093534
- 61.Lee S, Malhotra B, Creanga D et al (2009) A meta-analysis of the placebo response in antimuscarinic drug trials for overactive bladder. BMC Med Res Methodol 22:9–55Google Scholar